



The 34<sup>th</sup> Annual Meeting of  
the Asian Pacific Association for the Study of the Liver

# APASL 2025 BEIJING

Multidisciplinary Collaboration For Elimination & Cure


26–30 March 2025

China National Convention Center  
Beijing · China



## Industry Programming Guide

[www.apasl2025beijing.com](http://www.apasl2025beijing.com)




Scan the QR code  
for more details



<b>Exhibition Plan</b>	<b>04</b>
<b>Introduction</b>	<b>06</b>
<b>Acknowledgement</b>	<b>12</b>
<b>Satellite Symposia</b>	<b>14</b>
<b>Innovation Theater</b>	<b>18</b>

# Exhibition Plan





# Corporate Directory

**Booth No.**

300	APASL
201	AASLD
202	EASL
100	BTCH
104	CFHPC
102	CLH
106	CSH / CJH / JCTH
401	APASL 2026
105	Siemens Healthineers
107	QR Pharmaceuticals
111	BAHEAL MEDICAL
113	Boehringer Ingelheim
119	FuRui Co., Ltd.
128	Zhejiang Medicine
129	Opella
205	KaiJi XinCheng
206	Fujirebio
209	NCPC Genetech
213	GSK
229	Amoytop
305	HEC-Sunshine Lake Pharma
309	Orphalan

**Booth No.**

319	GSK
329	Hansoh Pharma
333	Haisco
405	Grifols
411	Abbott
413	HISKY / Hotgen / VIATRIS
419	Gilead Sciences
500	CTTQ
501	Vitalstar
505	Tasly
511	Sunlong
515	3S BIO
601	Abbott
604	Alfasigma
605	Eieling
606	Sanhome
613	Kawin
615	CMS
617	Rendu
619	Roche Diagnostics

# Introduction

## 105 Siemens Healthineers

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence.

## 107 QR Pharmaceuticals

Wuhan QR Pharmaceuticals Co., Ltd. is a national high-tech enterprise integrating production, R&D and sales, involving the whole industrial chain layout from APIs to preparations, from R&D to marketing, and has completed a number of innovative research projects with global leading level in the fields of liver disease, digestive disease, cardio cerebrovascular disease, autoimmune disease, respiratory disease, infectious diseases, etc.

## 111 BAHEAL MEDICAL

Baheal Medical, as a pharmaceutical industrialization platform, focuses its core business on the development, manufacturing, and commercialization of medical innovations. Currently, Baheal has established a comprehensive R&D and production system for both traditional Chinese and Western medicines. Relying on its robust commercialization capabilities and nationwide marketing network, Baheal has incubated several category-leading brands in areas such as liver disease and bone health, effectively optimizing medical practices through technological innovation.

## 113 Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain.

## 119 FuRui Co., Ltd.

Furui Co., Ltd. founded in 1998, is headquartered in Beijing with subsidiaries in France, Spain, Germany, The USA, Hong Kong China, and other regions. The company went public in China in 2010, with the stock code: 300049. The company specializes in the field of liver diseases, aiming to establish a global consensus on diagnosis and treatment of liver fibrosis. Through its excellent products and services, such as the Biejia-Ruangan compound and VCTE (Vibration-Controlled Transient Elastography) device-Fibroscan, promote the development of managed healthcare of liver diseases.

## 128 Zhejiang Medicine

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997. In October 1999, the company's shares were then listed on the Shanghai Stock Exchange. Zhejiang Medicine currently has nine major subsidiaries, and two research units. The company's leading product, natural vitamin E, holds an important position in the domestic market, especially in the field of fatty liver treatment.

## 129 Opella

Opella, Sanofi's Consumer Healthcare business unit, is the purest and third-largest player globally in the OTC & VMS market. Our mission is to make self-care as simple as it should be by being consumer-led always, with science at our core. Through our unique and balanced portfolio of more than 100 loved brands, we help more than half a billion consumers worldwide take their health in their hands.

### **205 KaiJi XinCheng**

Kaiji XinCheng is a mission-driven enterprise specializing in pharmaceutical research and development, integrated alongside strategic brand promotion. Committed to enabling patients access to innovative therapies and empowering healthcare professionals, we maintain specialized expertise in hepatology, oncology, and other therapeutic domains. Anchored in the corporate philosophy of "FORGE THE BRAND WITH QUALITY, CRAFT THE FUTURE WITH EXPERTISE", Kaiji XinCheng stands as a trusted partner dedicated to collaborating with global healthcare professionals in our shared pursuit of advancing human health.

### **206 Fujirebio**

Fujirebio is an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. We ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time.

### **209 NCPC Genetech**

NCPC Genetech Biotechnology Co., Ltd. is a high-tech biotechnology pharmaceutical enterprise of NCPC, located in Shijiazhuang High-tech Industrial Development Zone. Genetech was founded and entered into production in 1998. The business scope covers research and development of biologics, biotechnological products, medicinal products; production and distribution of vaccine and recombinant products; production of small volume injection; technological development, technological service and consulting; special road freight transport; warehousing service; the import and export of goods and technology, etc.

### **213 GSK**

GlaxoSmithKline (GSK) is a leading global biopharmaceutical company with innovative drugs and vaccines across multiple therapeutic areas. In liver diseases, GSK's medicines have benefited many patients, and its R&D progresses continuously. GSK also actively fulfills social responsibilities, contributing to global medical development and playing a crucial role in the pharmaceutical industry.

### **229 Amoytop**

Xiamen Amoytop Biotech Co., Ltd. (Amoytop Biotech) established in 1996, is an innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Amoytop Biotech is committed to providing better solutions for major diseases (such as viral hepatitis, malignant tumors and immunotherapy).

### **305 HEC-Sunshine Lake Pharma**

Sunshine Lake Pharma, founded in 2003, is a R&D-driven international pharmaceutical company. Adhering to the development strategies of "innovation" and "internationalization", Sunshine Lake Pharma has established a leading R&D platform, domestic first-class production and supply chain system, and a global marketing network. The company focuses on therapeutic areas such as infectious diseases, chronic illnesses, and oncology with 147 approved drugs globally and over 100 drugs under development. Sunshine Lake Pharma is the largest domestic manufacturer of oseltamivir and has launched 3 Class I innovative drugs in the field of chronic hepatitis C, Emetasivir Phosphate, Netanasvir Phosphate and Encofosbuvir.

### 309 Orphalan

Orphalan is an international orphan drug development and commercialization company founded in 2011 and headquartered in Paris, France. Our trientine tetrahydrochloride room temperature stable, scored tablet has been approved in more than 20 countries helping the Wilson's disease community. In China, it is marketed under the name, "Ke Pei Ou" (科佩欧®) and is commercially available since February 2025.

### 319 GSK

GlaxoSmithKline (GSK) is a leading global biopharmaceutical company with innovative drugs and vaccines across multiple therapeutic areas. In liver diseases, GSK's medicines have benefited many patients, and its R&D progresses continuously. GSK also actively fulfills social responsibilities, contributing to global medical development and playing a crucial role in the pharmaceutical industry.

### 329 Hansoh Pharma

Hansoh Pharma(03692.HK) is a leading pharmaceutical company in Greater China driven by innovation. It is committed to the treatment of major diseases in the areas of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases. To date, Hansoh Pharma has launched 7 innovative drugs to form a diverse commercial portfolio. Hansoh Pharma has been ranked among the top 100 global pharmaceutical companies and the top 3 best industrial enterprises in China in terms of pharmaceutical R&D pipeline for several years.

### 333 Haisco

Haisco Pharmaceutical Group is a biopharmaceutical company listed on the Chinese stock exchange, specializing in the research and development of innovative drugs. Headquartered in Chengdu, China, the company focuses its product portfolio on therapeutic areas including perioperative care, oncology, immunology, diabetes, and related complications. Haisco has built a robust pipeline of proprietary drug candidates, with multiple innovative drug programs currently undergoing clinical trials.

### 405 Grifols

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. Grifols is one of the largest plasma companies, with a growing network of centers worldwide. We develop this plasma into essential medicines used to treat chronic, rare and, at times, life-threatening conditions.

### 411 Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

### 413 HISKY

Hisky Medical, originating from Tsinghua University, boasts self-developed brands such as the iLivTouch® non-invasive liver disease management System, and CelTouch® confocal microprobe imaging system, which are widely applied in fields like hepatology and gastroenterology. The company has filed over 500 patents and has obtained international certifications including FDA and CE. Its operations span across dozens of countries worldwide, benefiting tens of millions of patients.

### 413 Hotgen

Beijing Hotgen Biotech Co.,Ltd.was established in June 2005, and is a biotechnology high-tech enterprise with the mission of "developing biotechnology to benefit human health." The company continuously explores independent innovation in diagnostic technology platforms, actively develops and expands liquid biopsy cancer early screening technology, and builds an industrial chain development strategy from diagnosis to treatment.

**413 VIATRIS**

VIATRIS is a global healthcare company committed to helping people around the world live healthier lives at every stage of life. Headquartered in the United States, with a global center in Shanghai, Viartis offers a wide and diverse range of products. Through its global supply chain, the company provides high-quality medicines to approximately 1 billion patients annually. Additionally, Viartis possesses strong scientific expertise to address the ever-evolving health challenges faced globally.

**419 Gilead Sciences**

Gilead Sciences, Inc. is a global leading biopharmaceutical company, founded in Foster City, California, in 1987. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Our ability to translate science into once-impossible advances has led to the commercialization of more than 29 life-changing therapies.

**500 CTTQ**

ChiaTai Tianqing Pharmaceutical Group Co., Ltd. is an innovation-driven pharmaceutical enterprise dedicated to pioneering medical advancements and the comprehensive development, production, and distribution of high-quality therapeutics. Committed to delivering patient-centric health solutions, the group has solidified its position as a nationally recognized hub for oncology and hepatology drug research and manufacturing. Designated as a National Key High-Tech Enterprise, it ranked 12th in the "2023 China Pharmaceutical Industry Top 100 Enterprises List".

**501 Vitalstar**

Founded in 2000, Vitalstar Biotechnology specializes in developing animal models for human diseases, with a focus on liver disease and oncology models. Utilizing cutting-edge gene editing technology, the company offers innovative solutions, including humanized liver reconstruction models. With 24 years of expertise, Vitalstar has supported numerous drug development companies in successful IND applications and published high-impact articles in CNS journals.

**505 Tasly**

As an international modern Chinese medicine enterprise, Tasly Pharma. (Stock code: 600535) is committed to developing into a leading solution provider of medicine and health services with global influence in China. With "people-oriented and precise innovation", Tasly Pharma. constantly promotes the progress of medicine and health to make every human-being can enjoy the beauty and hope of life.

**511 Sunlong**

Senlong Pharmaceutical Co., Ltd. is a new modern pharmaceutical enterprise integrating research and development, production, medical treatment and sales. The leading product "Anluohuaxian" is a product for the treatment of chronic hepatitis B and early and medium cirrhosis after hepatitis B. It is included in four national major special projects of the "12th Five-Year" and "13th Five-Year" of Chinese and Western medicine, and included in more than 20 guidelines and consensus.

**515 3S BIO**

3SBio is a leading bio-pharmaceutical company integrating research and development (R&D), manufacturing and commercialization, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Company owns more than 100 national invention patents and has launched more than 40 products into the market, covering several therapeutic areas such as nephrology, oncology, autoimmune diseases and dermatology. In the future, 3SBio will continue to uphold the concept of "Care for Life, Cherish Life, Create Life" to foster a world-leading biopharmaceutical company in China.

#### **601 Abbott**

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries. Abbott has more than 6,000 employees in China, headquartered in Shanghai. Connect with us at [www.abbott.com.cn](http://www.abbott.com.cn), [www.abbott.com](http://www.abbott.com), or WeChat [abbott\\_China](#)

#### **604 Alfasigma**

Alfasigma is a privately owned Italy based multinational company founded in 1948, 3rd largest company in the Italian retail market, Presence in about 100 countries, 2 R&D Lab centers and 6 manufacturing plants, 5 main therapeutic areas: Gastroenterology, Vascular, Rheumatology, Metabolic, Nutraceuticals & Medical foods.

#### **605 Eieling**

Eieling Technology Limited (hereinafter referred to as Eieling Technology) , a research and transformation enterprise of the Hong Kong Polytechnic University, was incorporated in the Hong Kong Science Park in 2018, and has always been committed to scientific and technological innovation and product development. In 2023, wholly-owned subsidiaries were set up in Shanghai and Shenzhen, entering a new stage. Eieling Technology always adheres to the development strategy of original research and innovation, focuses on the field of liver disease diagnosis and treatment, and insists on providing accurate and reliable intelligent liver health diagnosis solutions for global healthcare providers.

#### **606 Sanhome**

Nanjing Sanhome Pharmaceutical Co., Ltd, Pharmaceutical is a national key high-tech enterprise integrating new drug research and development, pharmaceutical production and independent academic promotion. With the mission of "enjoying the happiness of health for more people", it adheres to the enterprise goal of "becoming a world-class pharmaceutical enterprise" and strives to revitalize the national pharmaceutical industry and write a new chapter for the cause of human health.

#### **613 Kawin**

Founded in 2008, Beijing Kawin Technology Share-Holding Co., Ltd. is a biopharmaceutical company focused on viral and immune diseases, and committed to offering treatment solutions based on our biotech technology platforms. On February 8, 2021, Kawin was listed on Shanghai Stock Exchange STAR Market.

#### **615 CMS**

As a wholly-owned subsidiary of China Medical System Holdings Limited (867.HK), Shenzhen Kangzhe Pharmaceutical Co., Ltd. was established in 1995. It focused on specialty therapeutic fields such as cardio-cerebrovascular, central nervous system, gastroenterology, nephrology, etc. With its mature commercialization system and extensive academic resources, its major marketed products have gained leading academic and market positions.

#### **617 Rendu**

Founded in 2007, Shanghai Rendu Bio (688193) develops patented SAT tech (RNA real-time isothermal amplification). The company offers infectious disease detection reagents and fully automated testing equipment. Its HBV RNA test, the first globally approved, enables precise HBV therapy monitoring.

#### **619 Roche Diagnostics**

Roche Diagnostics is committed to developing and providing innovative and cost-effective diagnostic systems and solutions for early detection, prevention, diagnosis and monitoring of diseases so as to help healthcare professionals increase treatment outcome and make outstanding contributions to China's healthcare and the improvement of people's quality of life.

**Novo Nordisk**

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.

**Brii Biosciences**

Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai.

**AusperBio**

AusperBio is a clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, we strive to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, and to transform patient lives.

**BioKangTai**

Shenzhen Kangtai Biological Products Co., Ltd. (stock code: 300601) has now developed into a leading innovative biopharmaceutical enterprise in China with strong research capabilities, a rich product portfolio, industry-leading scale, and significant international progress. The company has five major R&D and industrial and possesses a diverse R&D platform. This provides a solid foundation for the transformation of cutting-edge vaccine technologies. Kangtai has 11 products that have been approved for market launch, including the world's first 60-microgram hepatitis B vaccine, the "dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine," and the first "four-dose" human diploid cell rabies vaccine approved in China.



# Acknowledgement

## DIAMOND SPONSORS



## GOLD SPONSORS



## SILVER SPONSORS



## BRONZE SPONSORS



# Acknowledgement

## SPONSORS



# Satellite Symposia

## 26 March 2025 (Wednesday)

---

**Gilead Science 15:45 - 17:45 Auditorium, Level 4**

---

### **Integration of Prevention and Medical Care for Hepatitis Elimination**

Chairs Lai WEI, *Beijing*; Yu WANG, *Beijing*

Speakers Gang CUI, *Beijing*; Sung Won LEE, *Seoul*; Jinlin HOU, *Guangzhou*; Jeremy LIM, *Singapore*; Zhongfu LIU, *Beijing*; Zengde LI, *Beijing*; Xiaoping TANG, *Guangzhou*; John WARD, *Decatur*; Jidong JIA, *Beijing*; Calvin Q. PAN, *New York*; Yasuhito TANAKA, *Kumamoto*; Lung Yi MAK, *Hong Kong*; Yoon Jun KIM, *Seoul* (Guests are listed by speaking order)

## 28 March 2025 (Friday)

---

**Amoytop 08:00 - 09:00 Plenary Hall A, Level 4**

---

**08:00 - 08:30**

### **Peginterferon Alpha-2b (Mippeginterferon alfa-2b, Pegbing®) Promotes Durable Functional Cure in Patients with Chronic Hepatitis B: a Multicenter, Randomized Controlled, Phase 3 Trial and its Long-term Follow-up Study**

Chair Jidong JIA, *Beijing*

Speaker Guiqiang WANG, *Beijing*

**08:30 - 09:00**

### **Progress and Achievements of the Everest Project for Functional Cure of Chronic Hepatitis B in China**

Chair Zhiliang GAO, *Guangzhou*

Speaker Chan XIE, *Guangzhou*

---

**GSK 12:00 - 13:00 Plenary Hall A, Level 4**

---

### **Destination Functional Cure in CHB: Are we there yet?**

Chair: Lai WEI, *Beijing*

Speakers: Grace WONG, *Hong Kong*; Wenhong ZHANG, *Shanghai*; Ed GANE, *Auckland*

---

**Opella 12:00 - 13:00 Function Hall A, Level 1**

---

### **MASLD: Early Screening, Treatment Strategies, and Quality of Life - Insights From New Clinical Evidence**

Chair Zobair M. YOUNOSSI, *Virginia*

Speakers Jiangao FAN, *Shanghai*; Norbert STEFAN, *Tübingen*; Jose D. SOLLANO, *Manila*

# Satellite Symposia

**Grifols**      **12:00 - 13:00**      **Function Hall B, Level 1**

## Optimizing Treatment of Patients with Cirrhosis Using Albumin

Chair      Huiguo DING, *Beijing*

Speakers   Bo FENG, *Beijing*; Rongqi WANG, *Shijiazhuang*

**Novo Nordisk**      **12:00 - 13:00**      **Function Hall C, Level 1**

## Act Now: Implementing a Multidisciplinary Approach to MASLD Management

Co-Chairs   Yimin MAO *Shanghai*; Lixin GUO, *Beijing*

Speakers   Huiying RAO, *Beijing*; Yingying LUO, *Beijing*

**Abbott**      **12:00 - 13:00**      **401, Level 4**

**12:00 - 12:30**

## Innovative Solution Supporting HCC Early Diagnosis and Enhancing Clinical Benefits: New Practice from China

Chair      Tian YANG, *Shanghai*

Speaker   Jingyu CAO, *Qingdao*

**12:30 - 13:00**

## CHB Functional Cure: A New Era of Precision Diagnosis and Treatment

Chair      Zhiliang GAO, *Guangzhou*

Speaker   Sujun ZHENG, *Beijing*

**Furui**      **12:00 - 13:00**      **403, Level 4**

## Managed Care Reformulates Comprehensive Liver Health Management Paradigm

Chairs      Xiaoyuan XU, *Beijing*; Yuemin NAN, *Shijiazhuang*

Speakers   Bingliang LIN, *Guangzhou*; Yongping CHEN, *Wenzhou*; Enqiang CHEN, *Chengdu*

**Orphalan**      **12:00 - 13:00**      **405, Level 4**

## New Development in Wilson's Disease Management - APASL/AASLD Guidelines and Clinical Experience Sharing

Chair      Jidong JIA, *Beijing*

Speakers   Wei ZHANG, *Beijing*; Robert G. GISH, *San Diego*

**Viatrix**      **12:00 - 13:00**      **406, Level 4**

## Updates in the Treatment of MAFLD: Integrative Approaches and Clinical Outcomes with Silymarin

Chair      Xiaoyuan XU, *Beijing*

Speakers   Xiong MA, *Shanghai*; Sakkarin CHIRAPONGSATHORN, *Bangkok*; Lee Ling LIM, *Kuala Lumpur*

## Satellite Symposia

---

**3S BIO**                      **12:00 - 13:00**    **407, Level 4**

---

**Clinical Management Symposium on Thrombocytopenia in Liver Disease**

Chairs        Xiaoyuan XU, *Beijing*; Yuemin NAN, *Shijiazhuang*

Speakers    Hong YOU, *Beijing*; Yan HUANG, *Changsha*

---

**GSK**                              **16:45 - 17:45**    **Function Hall A, Level 1**

---

**Destination Functional Cure in CHB: Can Innovative Mechanisms Overcome Roadblocks?**

Chair            Jinlin HOU, *Guangzhou*

Speakers    Yasuhito TANAKA, *Kumamoto*; Hong YOU, *Beijing*

---

**Gilead Science**    **16:45 - 17:45**    **Function Hall B, Level 1**

---

**Ride the Trend: China Guideline For Viral Hepatitis Elimination**

Chair            Lai Wei, *Beijing*

Speakers    Peng HU, *Chongqing*; Liang PENG, *Guangzhou*

---

## 29 March 2025 (Saturday)

---

**Gilead Science**    **12:15 - 13:15**    **Plenary Hall A, Level 4**

---

**Ride the Tide: The Future of Viral Hepatitis is Now**

Chair            Jidong JIA, *Beijing*

Speakers    Yuemin NAN, *Shijiazhuang*; Yasuhito TANAKA, *Kumamoto*; Chari COHEN, *Doylestown*.

---

**Hansoh**                              **12:15 - 13:15**    **Function Hall A, Level 1**

---

**Symposium on Innovative Nucleotide-Based Therapeutics**

Chair            Jinlin HOU, *Guangzhou*

Speakers    Xiaoguang DOU, *Shenyang*; Zhihong LIU, *Guangzhou*; Qing XIE, *Shanghai*

---

**Lilly**                                      **12:15 - 13:15**    **Function Hall B, Level 1**

---

**NIT Application in Phase 3 Clinical Trials for MAFLD/MASH Drug Development**

Chair            Minghua ZHENG, *Wenzhou*

Speaker        Junping SHI, *Hangzhou*

---

**Hisky**  
**Hotgen**  
**Viatris**                              **12:15 - 13:15**    **Auditorium, Level 4**

---

**Precision Diagnosis and Treatment of MASH: Technological Innovation and Practical Exploration**

Chairs        Robert G. GISH, *San Diego*; Jiangao FAN, *Shanghai*

Speakers    Wei AN, *Beijing*; Hong YOU, *Beijing*; Li LI, *Beijing*; Jie LI, *Beijing*; Rinaldi LESMANA, *Jakarta*;  
Graciela CASTRO, *Mexico City*

---

# Satellite Symposia

**Roche**  
**Diagnostics** 12:15 - 13:15 401, Level 4

## Total Management Solution for Liver Disease

Chair Xinxin ZHANG, *Shanghai*  
Speakers Wen XIE, *Beijing*; Qingxian CAI, *Shenzhen*

**Brii Biosciences** 12:15 - 13:15 402 (A+B), Level 4

## Harnessing the Immune System – Novel Approaches in HBV Cure

Host David MARGOLIS, *Durham*  
Speakers Man-Fung YUEN, *Hong Kong*; Antonio BERTOLETTI, *Singapore*; Jinlin HOU, *Guangzhou*

**Kawin** 12:15 - 13:15 403, Level 4

## Symposium on Hepatitis C: Advances in Diagnosis, Treatment, and Public Health Control Strategies

Co-Chairs Lai WEI, *Beijing*; Hong TANG, *Chengdu*; Zhongfu LIU, *Beijing*  
Speakers Qing XIE, *Shanghai*; Mingyang LI, *Beijing*; Jing ZHANG, *Beijing*

**Abbott** 12:15 - 13:15 405, Level 4

## Intrahepatic Cholestasis Diagnosis and Treatment

Chair Xiaoyuan XU, *Beijing*  
Speakers Jose MATO, *Derio*; Lungen LU, *Shanghai*

**Sanhome** 12:15 - 13:15 406, Level 4

## The Epidemiology of Hepatitis C and the Latest Advances in Prevention and Treatment

Chairs Yanhang GAO, *Changchun*; Chao WU, *Nanjing*; Qing XIE, *Shanghai*  
Speakers Huiying RAO, *Beijing*; Jian LI, *Beijing*; Junqi NIU, *Changchun*

**HEC-Sunshine**  
**Lake Pharma** 17:00 - 18:00 Function Hall A, Level 1

## Symposium: Helping to Eliminate Hepatitis C Virus by 2030

Chair Yuemin NAN, *Shijiazhuang*  
Speakers Xiaoping WU, *Nanchang*; Jiangbin WANG, *Jilin*

**GSK** 17:00 - 18:00 Function Hall B, Level 1

## Advancing the Functional Cure of CHB in China: Overcoming Challenges, Embracing the Future

Chair Jinlin HOU, *Guangzhou*  
Speakers Junqi NIU, *Changchun*; Huiying RAO, *Beijing*

# Innovation Theater

**27 March 2025 (Thursday)**

**Ballroom B, Level 1**

17:15 - 18:15

**Breakthrough · Innovation · Practice:**

**iLivTouch® Innovative Non-Invasive Solution for Liver Diagnosis**

**Breaking Through the Limitations of Traditional Diagnosis: Sharing New Parameters and Cutting-Edge Applications of TE Technology**

Presenter(s): Yameng SUN, *Beijing*

**Hands-On Teaching and Practical Training: Enhancing Diagnostic Efficiency and Accuracy**

Presenter(s): Diego ARUFE, *Buenos Aires*

**Supported by:** HISKY

**28 March 2025 (Friday)**

**Ballroom B, Level 1**

12:45 - 13:15

**iLivTouch® Innovative Solution For Liver Diagnosis**

Presenter(s): Yuanxia ZHANG, *Wuxi*

**The Application of CK18 in the Population with Fatty Liver**

Presenter(s): Fang CHEN, *Beijing*

**Legalon® Brand Promotion and Concept Communication in the Chinese Market**

Presenter(s): Xiaofeng FAN, *Shanghai*

**Supported by:** HISKY, HOTGEN, VIATRIS

13:30 - 14:00

**Evaluation of Antiviral and Immunomodulatory Effects of Tenofovir Amibufenamide in Chronic HBV-replication Mouse Models**

Presenter(s): Jia LIU, *Wuhan*

**Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in Patients with Hepatitis B Cirrhosis: A Retro-prospective Observational Study**

Presenter(s): Ruochan CHEN, *Changsha*

**Supported by:** Hansoh

14:15 - 14:45

**Accelerating Toward a Cure: Together for 2030 Elimination Goal  
Media Salon**

Opening Speaker: Sherman YU, *Shanghai*

Panel Members: Qing XIE, *Shanghai*; Fuqiang CUI, *Beijing*; Dickens THEODORE, *Durham*

Moderator: Maggie CHEN, *Shanghai*

**Supported by:** GSK



# Innovation Theater

15:00 -15:30

## **GRIFOLS Albumin: from donors to patients**

Presenter(s): Marta FERRANDO, *Barcelona*

**Supported by:** Grifols

15:45 - 16:15

## **Showcase LIVERNEXT AI -AI tool to help diagnose and manage MASLD/MAFLD**

Presenter(s): Branko POPOVIC, Francesc SOTOS, Adam TANG, Mary WANG

**Supported by:** Opella

16:30 - 17:00

## **Roche's Solutions for Liver Management**

### **Partnering with health systems to enable better end-to-end care for Chronic Liver Disease**

Presenter(s): Devmanyu SINGH, *Singapore*

### **Roche liver care integrated solution**

Presenter(s): Songgang GU, *Shanghai*

**Supported by:** Roche Diagnostics

**29 March 2025 (Saturday)**

**Ballroom B, Level 1**

10:00 - 10:30

## **First in Class Delpar for PBC**

Presenter(s): Barry CRITTENDEN, *San Francisco*; Grace CHEE, *San Francisco*

**Supported by:** Gilead Sciences

10:45 - 11:15

## **One Press, Liver Insight | FibroScan® Guided VCTE China Premiere & Live Demo**

Presenter(s): Christine ZHANG, *Shenzhen*

**Supported by:** Echosens

11:30 - 12:00

## **INNOVATION LEADING BIOPHARMA EVOLUTION**

Presenter(s): Ge GE, *Xiamen*

**Supported by:** Amoytop

13:00 - 13:30

## **ABBOTT and Partnering Hepatitis Elimination Efforts-across the World**

Presenter(s): Priyank DUBEY, *Singapore*

### **Partnering Hepatitis Elimination Efforts in China**

Presenter(s): Meng DAI, *Shanghai*

**Supported by:** Abbott

[illegible]

